ES2218814T3 - Uso de queleritrina y radiacion para el tratamiento de tumores. - Google Patents

Uso de queleritrina y radiacion para el tratamiento de tumores.

Info

Publication number
ES2218814T3
ES2218814T3 ES98914302T ES98914302T ES2218814T3 ES 2218814 T3 ES2218814 T3 ES 2218814T3 ES 98914302 T ES98914302 T ES 98914302T ES 98914302 T ES98914302 T ES 98914302T ES 2218814 T3 ES2218814 T3 ES 2218814T3
Authority
ES
Spain
Prior art keywords
cheleritrine
radiation
tumor treatment
apoptosis
irradiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98914302T
Other languages
English (en)
Spanish (es)
Inventor
Ralph R Weichselbaum
Jose Quintans
Steven J Chmura
Donald W Kufe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Arch Development Corp
Original Assignee
Dana Farber Cancer Institute Inc
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Arch Development Corp filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2218814T3 publication Critical patent/ES2218814T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES98914302T 1997-03-25 1998-03-25 Uso de queleritrina y radiacion para el tratamiento de tumores. Expired - Lifetime ES2218814T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/826,814 US6025365A (en) 1997-03-25 1997-03-25 Chelerythrine and radiation combined tumor therapy

Publications (1)

Publication Number Publication Date
ES2218814T3 true ES2218814T3 (es) 2004-11-16

Family

ID=25247609

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98914302T Expired - Lifetime ES2218814T3 (es) 1997-03-25 1998-03-25 Uso de queleritrina y radiacion para el tratamiento de tumores.

Country Status (12)

Country Link
US (1) US6025365A (enExample)
EP (1) EP0971710B1 (enExample)
JP (1) JP2001521552A (enExample)
CN (1) CN1172668C (enExample)
AT (1) ATE267599T1 (enExample)
AU (1) AU737613B2 (enExample)
CA (1) CA2284992A1 (enExample)
DE (1) DE69824165T2 (enExample)
DK (1) DK0971710T3 (enExample)
ES (1) ES2218814T3 (enExample)
PT (1) PT971710E (enExample)
WO (1) WO1998042339A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426351B1 (en) * 2000-08-11 2002-07-30 Dana-Farber Cancer, Inc. Chelerythrine-based therapies for cancer
WO2003005965A2 (en) * 2001-07-11 2003-01-23 Musc Foundation For Research Development Modulators of ceramidase and methods of use based thereon
US20030028097A1 (en) * 2001-08-03 2003-02-06 D'amico Anthony V. Immobilizer probe system and method
WO2004016211A2 (en) * 2002-08-08 2004-02-26 Vanderbilt University Pi3k antagonists as radiosensitizers
JP2004284961A (ja) * 2003-03-19 2004-10-14 Okinawa Pref Gov 抗腫瘍成分をサルカケミカンから抽出した製剤、食品または食品添加物
CN1292750C (zh) * 2003-06-02 2007-01-03 张平 植物来源总生物碱组合物及其药物制剂
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
KR100822887B1 (ko) 2006-10-12 2008-04-17 한국생명공학연구원 치매의 치료 또는 예방을 위한 조성물
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
CN101904849A (zh) * 2010-08-19 2010-12-08 苏州大学 血根碱制备肿瘤放射治疗增敏药物的应用
CN102552264A (zh) * 2012-02-28 2012-07-11 苏州大学 血根碱在制备电离辐射防护剂中的应用
CN116407537A (zh) * 2023-03-03 2023-07-11 长春中医药大学 一种白屈菜红碱在制备用于治疗卵巢癌的药物中的用途
CN118304300B (zh) * 2024-04-12 2025-03-14 儋州市人民医院 一种具有麻醉作用的组合物及其在制备麻醉药物中的应用
CN119548502A (zh) * 2024-11-19 2025-03-04 中国药科大学 白屈菜红碱在制备黑色素瘤治疗药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US209331A (en) * 1878-10-29 Improvement in medical compounds
US433257A (en) * 1890-07-29 Salve
US2344830A (en) * 1940-08-15 1944-03-21 Wisconsin Alumni Res Found Composition of matter for the chemical fixation of diseased tissue preparatory for surgical removal
US4145412A (en) * 1977-02-14 1979-03-20 Vipont Chemical Company Composition for application to oral cavity and method for preparation thereof
US4406881A (en) * 1980-05-20 1983-09-27 Vipont Laboratories Antimicrobial agent
US4376115A (en) * 1980-08-05 1983-03-08 Mccrorey Howard S Method and composition for treating teeth and method for preparing same
US4599228A (en) * 1981-01-19 1986-07-08 Vipont Laboratories, Inc. Antimicrobial agent
US5324520A (en) * 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
AU6714396A (en) * 1995-07-28 1997-02-26 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
HUP9601096A2 (hu) * 1996-04-26 1998-01-28 János Aradi Anti-HIV-aktivitással rendelkező gyógynövényalapú gyógyászati és gyógyhatású készítmény,és vegyületek

Also Published As

Publication number Publication date
CA2284992A1 (en) 1998-10-01
PT971710E (pt) 2004-09-30
CN1172668C (zh) 2004-10-27
CN1255061A (zh) 2000-05-31
AU737613B2 (en) 2001-08-23
DK0971710T3 (da) 2004-09-27
ATE267599T1 (de) 2004-06-15
US6025365A (en) 2000-02-15
JP2001521552A (ja) 2001-11-06
WO1998042339A1 (en) 1998-10-01
DE69824165T2 (de) 2005-06-09
EP0971710A1 (en) 2000-01-19
DE69824165D1 (de) 2004-07-01
AU6869398A (en) 1998-10-20
EP0971710B1 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
ES2218814T3 (es) Uso de queleritrina y radiacion para el tratamiento de tumores.
US6828576B2 (en) UV LED light projection method and apparatus
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
BR0115087A (pt) Membro radioativo para uso em braquiterapia e métodos de fazer um membro radioativo e de tratar uma condição que responda a terapia por radiação
ZA202306838B (en) Diffusing alpha-emitters radiation therapy with enhanced beta treatment
ES8500066A1 (es) Procedimiento para preparar un aposito de gel adherente no rigido esteril y transparente.
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
ES2191192T3 (es) Tienopirimidinas.
SE9602799D0 (sv) Anordningar för elektrodynamisk strålterapi av tumörsjukdomar (cancer)
ES2165349T3 (es) Fuente de rayos x miniaturizada, de baja potencia.
CY1114622T1 (el) Συνδυασμοι για την αγωγη παθησεων ενεχοντας υπερπλασια, μεταναστευση ή αποπτωση κυτταρων των κυτταρων μυελωματος, ή αγγειογενεση
GB0119937D0 (en) High definition radiation treatment with an intensity modulating multi-leaf collimator
ES2143463T3 (es) Terapia genica contra enfermedades proliferativas celulares.
AR012626A1 (es) Una composicion farmaeutica que comprende un derivado o análogo de leptina como inhibidor de la proliferacion de células de tumor y el uso de dicha composicion farmaceutica para la manufactura de medicamento para el tratamiento de tumores
ES2141109T3 (es) Procedimiento para la prevencion de la reestenosis despues de la reconfiguracion de los vasos del organismo.
AR022404A1 (es) Metodo y agentes para la terapia de radiacion mejorada
FI970918A7 (fi) Yhdisteet ja menetelmät syövän hoitamiseksi
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
AR021967A1 (es) Agentes fototerapeuticos de alta energia
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
ES2139002T3 (es) Terapia medicamentosa citotoxica.
ES2103854T3 (es) Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia.
ES2179204T3 (es) Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.
ES2172558T3 (es) Lubricante compatible con radiaciones para dispositivos medicos.
ES2058161T3 (es) Producto activo para la lucha contra tumores.